Zhejiang Huakang Pharmaceutical Co., Ltd. / Fundamentals
Income statement
- Net revenue
€395.91M - Cost of goods sold
€316.72M - Gross profit
€79.20M - SG&A expenses
€8.07M - R&D expenses
€15.97M - EBITDA
€63.11M - D&A
€21.30M - EBIT
€37.50M - Interest expenses
€7.12M - EBT
€35.35M - Tax expenses
€3.03M - Net income
€31.39M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€23.20M - Changes in working capital
€0.00 - Operating cash flow
€28.98M - Capex
€100.43M - Other investing cash flow
-€18.98M - Net investing cash flow
-€108.55M - Total cash dividends paid
-€22.01M - Issuance of common stock
€0.00 - Debt repayment
€95.91M - Other financing cash flow
-€23.53M - Net financing cash flow
€47.29M - Foreign exchange effects
€1.14M - Net change in cash
-€27.67M - Cash at end of period
€59.48M - Free cash flow
€129.41M
Balance sheet
- Cash and cash equivalents
€95.25M - Cash and short-term investments
€98.82M - Total receivables
€97.04M - Inventory
€91.19M - Other current assets
€80.22M - Total current assets
€367.27M - Property, plant & equipment
€434.26M - Goodwill
€41.19M - Intangible assets
€35.92M - Long-term investments
€11.48M - Other non-current assets
€6.57M - Total non-current assets
€532.79M - Total assets
€900.05M - Accounts payable
€111.12M - Short-term debt
€64.01M - Other current liabilities
€44.72M - Total current liabilities
€222.96M - Long-term debt
€264.60M - Deferred tax liabilities
€9.36M - Other non-current liabilities
€0.00 - Total non-current liabilities
€291.20M - Total liabilities
€514.16M - Common stock
€36.06M - Retained earnings
€140.75M - Other equity
€0.00 - Total equity
€385.90M - Total liabilities and shareholders' equity
€900.05M
Company information
- Market capitalization
€574.54M - Employees
1.4K - Enterprise Value
€6.62B
Company ratios
- Gross margin
-
20.0% Even with peer group: 18.3% - EBITDA margin
-
15.9% Even with peer group: 12.4% - EBIT margin
-
9.5% Better than peer group: 2.7% - EBT margin
-
8.9% Even with peer group: 5.6% - Net margin
-
7.9% Even with peer group: 4.2% - ROE
-
8.1% Even with peer group: 6.1% - ROA
-
3.5% Even with peer group: 7.3% - Asset turnover
-
44.0% Much worse than peer group: 91.4% - FCF margin
-
-18.0% Worse than peer group: -3.4% - FCF yield
-12.4% - Efficiency ratio
84.1% - Net sales per employee
-
€293.27K - Net income per employee
-
€23.25K